These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 17067225)

  • 1. [Waldemström s macroglobulinemia].
    Khosravi Shahi P; del Castillo Rueda A; Díaz Muñoz de la Espada VM
    An Med Interna; 2006 Jun; 23(6):291-3. PubMed ID: 17067225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
    Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Waldenström's macroglobulinemia.
    Dimopoulos MA; Anagnostopoulos A
    Best Pract Res Clin Haematol; 2005; 18(4):747-65. PubMed ID: 16026748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waldenström's macroglobulinemia.
    McKenna JA
    Clin J Oncol Nurs; 2002; 6(5):283-6. PubMed ID: 12240489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Owen RG; Treon SP; Al-Katib A; Fonseca R; Greipp PR; McMaster ML; Morra E; Pangalis GA; San Miguel JF; Branagan AR; Dimopoulos MA
    Semin Oncol; 2003 Apr; 30(2):110-5. PubMed ID: 12720118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognizing hyperviscosity syndrome in patients with Waldenstrom macroglobulinemia.
    Mullen EC; Wang M
    Clin J Oncol Nurs; 2007 Feb; 11(1):87-95. PubMed ID: 17441400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Waldenström's macroglobulinemia].
    Brouet JC
    Rev Prat; 2006 Jan; 56(1):25-30. PubMed ID: 16548246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How we treat Waldenström's macroglobulinemia.
    Dimopoulos MA; Merlini G; Leblond V; Anagnostopoulos A; Alexanian R
    Haematologica; 2005 Jan; 90(1):117-25. PubMed ID: 15642678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapies in Waldenström macroglobulinemia.
    Burwick N; Roccaro AM; Leleu X; Ghobrial IM
    Curr Opin Investig Drugs; 2008 Jun; 9(6):631-7. PubMed ID: 18516762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
    Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and management of Waldenstrom's macroglobulinemia.
    Dimopoulos MA; Kyle RA; Anagnostopoulos A; Treon SP
    J Clin Oncol; 2005 Mar; 23(7):1564-77. PubMed ID: 15735132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Waldenström macroglobulinaemia.
    Fonseca R; Hayman S
    Br J Haematol; 2007 Sep; 138(6):700-20. PubMed ID: 17672883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The treatment of Waldenström macroglobulinemia and the therapy of diseases caused by monoclonal IgM gammaglobulin].
    Adam Z; Scudla V; Krejcí M; Korístek Z
    Vnitr Lek; 2008 Jan; 54(1):68-83. PubMed ID: 18390120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Waldenström macroglobulinemia.
    Gertz MA
    Hematology; 2012 Apr; 17 Suppl 1():S112-6. PubMed ID: 22507796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.
    Varettoni M; Zibellini S; Defrancesco I; Ferretti VV; Rizzo E; Malcovati L; Gallì A; Porta MGD; Boveri E; Arcaini L; Candido C; Paulli M; Cazzola M
    Haematologica; 2017 Dec; 102(12):2077-2085. PubMed ID: 28983055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk stratification in Waldenström macroglobulinemia.
    Morel P; Merlini G
    Expert Rev Hematol; 2012 Apr; 5(2):187-99. PubMed ID: 22475287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurological manifestations of Waldenström macroglobulinemia.
    Baehring JM; Hochberg EP; Raje N; Ulrickson M; Hochberg FH
    Nat Clin Pract Neurol; 2008 Oct; 4(10):547-56. PubMed ID: 18813229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Waldenström's macroglobulinemia. An overview of its clinical, biochemical, immunological and therapeutic features and our series of 121 patients collected in a single center.
    Merchionne F; Procaccio P; Dammacco F
    Crit Rev Oncol Hematol; 2011 Oct; 80(1):87-99. PubMed ID: 21036057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab-based treatments in Waldenström's macroglobulinemia.
    Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia.
    Tedeschi A; Conticello C; Rizzi R; Benevolo G; Laurenti L; Petrucci MT; Zaja F; Varettoni M
    Hematol Oncol; 2019 Apr; 37(2):117-128. PubMed ID: 30192023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.